Engineering Antibodies with C-Terminal Sortase-Mediated Modification for Targeted Nanomedicine.


Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2019
Historique:
entrez: 24 7 2019
pubmed: 25 7 2019
medline: 9 4 2020
Statut: ppublish

Résumé

The current advances in nanoengineered materials coupled with the precise targeting capability of recombinant antibodies can create nanoscale diagnostics and therapeutics which show enhanced accumulation and extended retention at a target tissue. Smaller antibodies such as single-chain variable fragments (scFv) preserve the selective and strong binding of their parent antibody to their antigen with the benefits of low immunogenicity, more efficient tissue penetration and easy introduction of functional residues suitable for site-specific conjugation. This is of high importance as nonspecific antibody modification often involves attachment to free cysteine or lysine amino acids which may reside in the active site, leading to reduced antigen binding.In this chapter, we outline a facile and versatile chemoenzymatic approach for production of targeted nanocarrier scFv conjugates using the bacterial trans-peptidase Sortase A (Srt A). Srt A efficiently mediates sequence-specific peptide ligation under mild conditions and has few undesirable side reactions. We first describe the production, purification and characterization of Srt A enzyme and a scFv construct which targets activated platelets, called scFv

Identifiants

pubmed: 31332748
doi: 10.1007/978-1-4939-9654-4_6
doi:

Substances chimiques

Antibodies 0
Antigens 0
Azides 0
Bacterial Proteins 0
Immunoconjugates 0
Recombinant Proteins 0
Single-Chain Antibodies 0
Aminoacyltransferases EC 2.3.2.-
sortase A EC 2.3.2.-
Cysteine Endopeptidases EC 3.4.22.-
Lysine K3Z4F929H6
Cysteine K848JZ4886

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-80

Auteurs

Rania A Hashad (RA)

NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia.

Jaclyn L Lange (JL)

NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia.

Natasha C W Tan (NCW)

NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia.

Karen Alt (K)

NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia. karen.alt@monash.edu.

Christoph E Hagemeyer (CE)

NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia. christoph.hagemeyer@monash.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH